Free tool
FAERS Monitor: Orabloc
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022466 or its brand name (Orabloc, Articaine Hydrochloride, Epinephrine Bitartrate). Reports on generic versions are filed under their own applications.
Reports
180
Serious
76
42% of reports
Hospitalization
21
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective56
- dizziness10
- loss of consciousness9
- hypoaesthesia oral8
- paraesthesia8
- therapeutic product effect prolonged8
- anaphylactic shock7
- drug effect prolonged7
- nausea6
- pain6
- drug effect incomplete5
- hypoaesthesia5
- malaise5
- palpitations5
- urticaria5
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 3 |
| 2014 | 4 |
| 2015 | 5 |
| 2016 | 9 |
| 2017 | 25 |
| 2018 | 7 |
| 2019 | 15 |
| 2020 | 16 |
| 2021 | 10 |
| 2022 | 10 |
| 2023 | 26 |
| 2024 | 24 |
| 2025 | 17 |
| 2026 | 6 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,979 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| therapeutic product effect prolongedSignal | 8 | 2102.8 | 1061.3 | 14,510 |
| drug effect prolongedSignal | 7 | 1502.3 | 723.2 | 8,940 |
| hypoaesthesia oralSignal | 8 | 62.1 | 31.5 | 422 |
| anaphylactic shockSignal | 7 | 31.7 | 15.4 | 179 |
| drug effect incompleteSignal | 5 | 16.1 | 6.8 | 57 |
| loss of consciousnessSignal | 9 | 8.2 | 4.3 | 50 |
| paraesthesiaSignal | 8 | 5.9 | 3.0 | 28 |
| palpitationsSignal | 5 | 5.0 | 2.1 | 12 |
| drug ineffectiveSignal | 56 | 5.0 | 4.0 | 185 |
| hypoaesthesiaSignal | 5 | 3.9 | 1.6 | 8 |
| urticariaSignal | 5 | 3.5 | 1.5 | 7 |
| dizzinessSignal | 10 | 2.3 | 1.3 | 7 |
| malaise | 5 | 1.3 | 0.6 | 0 |
| pain | 6 | 1.1 | 0.5 | 0 |
| nausea | 6 | 0.9 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.